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Chapter 6
Precision-cut kidney slices (PCKS) to study development of 
renal fibrosis and efficacy of drug targeting ex vivo
F. Poosti, B. T. Pham, D. Oosterhuis, K. Poelstra, 
H. van Goor, P. Olinga, J.L. Hillebrands
Disease Models and Mechanisms 2015, 8(10), 1227-1236.
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ABSTRACT 
 Background: Renal fibrosis is a serious clinical problem forming the utmost cause of need for renal replacement therapy. No adequate preventive or 
curative therapy is available that can be clinically used to specifically target renal fibrosis. 
The search for new efficacious treatment strategies is therefore warranted. Although in vitro 
models using homogeneous cell populations have contributed to the understanding of the 
pathogenetic mechanisms involved in renal fibrosis, these models poorly mimic the complex 
in vivo milieu. Therefore, here we evaluated a precision-cut kidney slice (PCKS) model as a 
new, multicellular ex vivo model to study development of fibrosis and the prevention thereof 
using antifibrotic compounds. 
 Methods: Precision-cut slices (200-300 μm thickness) were prepared from healthy C57BL/6 mouse kidneys using a Krumdieck tissue slicer. To induce 
changes mimicking the fibrotic process, slices were incubated with TGFβ1 (5 ng/ml) for 48 
h in the presence or absence of the antifibrotic cytokine IFNγ (1 µg/ml) or an IFNγ conjugate 
which is targeted to the PDGFRβ (PPB-PEG-IFNγ). Following culture, tissue viability (ATP-
content) and expression of α-SMA, fibronectin, collagen I, and collagen III were determined 
using real-time PCR and immunohistochemistry. 
 Results: Slices remained viable up to 72 h of incubation and no significant effects of TGFβ1 and IFNγ on viability were observed. TGFβ1 markedly 
increased α-SMA, fibronectin, and collagen I mRNA and protein expression levels. IFNγ and 
PPB-PEG-IFNγ significantly reduced TGFβ1-induced fibronectin, collagen I and collagen III 
mRNA expression which was confirmed by immunohistochemistry.
 Conclusions: The PKCS model is a novel tool to test the pathophysiology of fibrosis and to screen the efficacy of antifibrotic drugs ex vivo in a multicellular 
and pro-fibrotic milieu. Major advantage of the slice model is that it can be used not only for 

































 Renal fibrosis is a major contributor to the development of chronic kidney 
disease (CKD) and is characterized by accumulation of myofibroblasts and excessive 
extracellular matrix deposition (Eddy, 2011; Friedman et al., 2003). CKD culminates 
in End-Stage Renal Disease (ESRD) eventually, resulting in significant morbidity 
and mortality for which the only available therapy is dialysis or renal transplantation 
(Levey et al., 2007). The pathophysiology of renal fibrosis is not fully understood 
and hitherto no adequate preventive or curative therapy is clinically available (Boor 
et al., 2010). Research focusing on unraveling the pathophysiology of renal fibrosis is 
therefore warranted. Traditionally, renal research is performed in in vitro cell culture 
systems or small rodent models as well as on human renal biopsies or explants 
(Westra et al., 2013). Despite the fact that in vitro experiments using homogeneous 
single cell preparations allow functional analyses of a specific cell type, the major 
disadvantage obviously is lack of cell heterogeneity and cellular microarchitecture; 
phenomena that are undoubtedly involved in determining and driving the fibrotic 
process (Vickers et al., 2005; Westra et al., 2013). Because of ethical constraints, the 
use of animal models is increasingly discouraged. Furthermore, use of human tissue 
biopsies is by definition descriptive in nature and prohibits functional studies. 
 The availability of an ex vivo model system that does allow functional analyses 
on the development of renal fibrosis is therefore highly desired. Recently, precision 
cut tissue slices (PCTS) have been increasingly used to study the development of 
liver fibrosis (Hadi et al., 2013; Westra et al., 2014a; Westra et al., 2014b). In this 
model cell-cell and cell-extracellular matrix interactions are preserved. As yet, it 
is unknown whether precision-cut kidney slices (PCKS) can be used to study the 
development of renal fibrosis and to screen the efficacy of antifibrotic compounds, 
e.g. IFNγ. IFNγ is a pleiotropic cytokine produced by various activated immune cells 
including NK cells and T cells (Farrar and Schreiber, 1993). In addition to its pro-
inflammatory effects, IFNγ has prominent antifibrotic effects. IFNγ is able to inhibit 
fibroblast activation and proliferation, and also reduces extracellular matrix synthesis 
(Lee et al., 2013; Oldroyd et al., 1999; Strutz et al., 2000; Weng et al., 2005; Yao 
et al., 2011). These properties make IFNγ a potential molecule for therapeutic use 
to target fibrosis. However, the short half-life and undesirable systemic side effects 
clearly limit clinical utility of IFNγ as an antifibrotic drug (Cleland et al., 1996; Gu 
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et al., 2005; King et al., 2009). To overcome these problems, we employed a drug-
targeting strategy in which IFNγ was targeted specifically to activated myofibroblasts 
in animal models of liver and kidney fibrosis using the PDGFRβ as docking receptor 
for the PPB-PEG-IFNγ conjugate (PPB: PDGFRβ-recognizing receptor) (Bansal et 
al., 2011a; Bansal et al., 2011b; Bansal et al., 2011c; Bansal et al., 2012; Poosti et al., 
2014).
 The aim of the present study was to validate the precision-cut kidney slice 
(PCKS) model for the development of TGFβ1-induced renal fibrosis and to evaluate 

































Viability of mouse kidney slices (mPCKS) during incubation
 In order to determine viability of mPCKS, ATP levels per mg of protein 
were assessed directly after preparation of slices, and after 1, 6, 12, 24, 48, and 72 h 
of incubation (Figure 1A). Kidney slices remained viable up to 72 h of incubation; 
however, a minor, non-significant decrease in ATP levels was observed after 24 h of 
incubation. Up to 72 h slices retained constant ATP levels. Since the morphology of 
kidney slices started to deteriorate after 72 h of incubation (based on PAS staining, 
data not shown), the experiments with TGFβ1 and antifibrotic compounds were 
conducted with a maximal culture time of 48 h. In a separate experiment, we first 
examined the viability of slices after 48 h of incubation with or without TGFβ1 in 
the presence of free IFNγ, PPB-PEG-IFNγ or PPB-HSA. As shown in Figure 1B, 
TGFβ1 did not significantly alter ATP content. Furthermore, free IFNγ, PPB-PEG-
IFNγ, or PPB-HSA did not affect ATP levels independent of presence or absence of 
TGFβ1.  
Uptake of FITC-lysozyme by mPCKS 
 We next analyzed whether exogenously added proteins can reach the center 
of mPCKS during incubation. As model protein we used FITC-conjugated lysozyme. 
As shown in Figure 1C, after 1 h of incubation, FITC-conjugated lysozyme was 
only present at the outer surface area of mPCKS. However, after 3 h of incubation 
fluorescence was detected throughout the thickness of the slices with high staining 
intensity (depicted in green) also observed within the center of the slice.
Biological activity of IFNγ and PPB-PEG-IFNγ ex vivo 
 To determine the biological activity of free IFNγ and PPB-PEG-IFNγ, we 
assessed major histocompatibility class II (MHC II) expression which is known to 
be upregulated by IFNγ (Bansal et al., 2011a). Expression of MHC II in response 
to IFNγ was analyzed in TGFβ- and non-TGFβ-incubated slices. qRT-PCR results 
showed that incubation of kidney slices in the presence of both free IFNγ and PPB-
PEG-IFNγ caused a significant upregulation of MHC II expression compared with 
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medium, effects that were not influenced by TGFβ1 (Figure 2A). However, PPB-
HSA (the PDGFRβ-specific drug delivery carrier without IFNγ) did not induce 
MHC II expression. These data indicate that IFNγ and PPB-PEG-IFNγ retained their 
biological activity in kidney slices.
Figure 1.  Effect of incubation time and conditions on mPCKS viability, and uptake of FITC-lysozyme 
by mPCKS. (A) Non-cultured normal kidney slices (n = 3) directly after the slicing procedure (0) and 
after different incubation intervals. (B) Effect of 48 h of incubation with TGFβ1 on ATP content of 
mPCKS in the presence of IFNγ, PPB-PEG-IFNγ and PPB-HSA with or without TGFβ1. (C) mPCKS 
were incubated with FITC-lysozyme (model protein) for 1 h (left panel) and 3 h (right panel) to 
determine penetration of exogenously added protein in mPCKS (magnification: 100×, inset: 400×).
PDGFRβ expression in mPCKS
 We recently showed increased interstitial PDGFRβ expression in both 
human and mouse fibrotic renal tissue which co-localized with α-SMA positive 
interstitial myofibroblasts (Poosti et al., 2015). High expression of PDGFRβ on 
interstitial myofibroblasts indicates that this receptor is an appropriate target for 
































in the presence of TGFβ1 are also characterized by PDGFRβ expression. As shown 
in Figure 2B, mPCKS cultured with medium but without TGFβ1 clearly expressed 
PDGFRβ which was not increased by TGFβ1. A clear, but non-significant reduction 
in PDGFRβ expression was observed after incubation in the presence of free IFNγ 
and PPB-PEG-IFNγ (Figure 2B).    
Induction of α-SMA and ECM expression in mPCKS by TGFβ1
 To study development of (pre)fibrosis in mPCKS in the presence of TGFβ1, 
mRNA expression of fibrosis markers was determined after 48 h of incubation with 
TGFβ1 (5 ng/ml). As shown in Figure 3, we observed significant upregulation of 
α-SMA (A), fibronectin (B), and collagen I (C) mRNA expression upon incubation 
with TGFβ1 compared to non-TGFβ1 incubated control (medium) slices. TGFβ1 
also increased expression of collagen III, however without reaching the level of 
statistical significance (p = 0.08). We next tested by immunohistochemistry whether 
increased mRNA expression of fibrosis markers also translated into altered protein 
expression levels. As shown in Figure 4A (two upper rows), incubation with TGFβ1 
indeed markedly increased α-SMA, fibronectin and collagen III expression.
Effect of free IFNγ and PPB-PEG-IFNγ on the expression of fibrosis markers
 To investigate whether free IFNγ and PPB-PEG-IFNγ treatment ameliorates 
fibrosis, qRT-PCR analysis was performed on fibrotic and healthy control slices. 
As already shown in Figure 3, TGFβ1 induced α-SMA, fibronectin, collagen I, 
and collagen III mRNA expression. Figure 5A depicts a schematic representation 
of the targeting strategy in which IFNγ is targeted towards PDGFRβ-expressing 
myofibroblasts using the PPB-PEG-IFNγ conjugate. In cultured slices incubated with 
TGFβ plus either IFNγ or PPB-PEG-IFNγ, mRNA expression levels for fibronectin, 
collagen I, and collagen III were significantly reduced compared to slices incubated 
with TGFβ alone (Figure 5C-E). IFNγ and PPB-PEG-IFNγ also showed somewhat 
reduced α-SMA expression (Figure 5B), however without reaching the level of 
statistical significance. To determine whether IFNγ, PPB-PEG-IFNγ, and PPB-HSA 
have protective effects in spontaneous induction of fibrosis, kidney slices were also 
incubated with the aforementioned compounds in the absence of TGFβ1. In this 
condition, we did not observe significant reduction of fibrosis maker expression in 
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the presence of free IFNγ or PPB-PEG-IFNγ, although clear trends were observed 
for collagen I (Figure 5D) and collagen III (Figure 5E).
Figure 2.  MHC II and PDGFRβ expression in mPCKS. (A) mRNA expression of MHC II in pre-
fibrotic (+TGFβ1) and non-fibrotic (−TGFβ1) kidney slices treated with IFNγ, PPB-PEG-IFNγ or 
PPB-HSA. (B) mRNA expression of PDGFRβ in pre-fibrotic (+TGFβ1) and non-fibrotic (−TGFβ1) 
































Figure 3. TGFβ1 (5 ng/ml) induces expression of fibrotic markers in mPCKS. mRNA expression of 
(A) α-SMA, (B) fibronectin, (C) collagen I and (D) collagen III in mouse kidney slices after 48 h of 
incubation. *p < 0.05, ***p < 0.001 versus medium.
To determine whether mRNA expression profiles also translated into 
differential protein expression levels, immunohistochemistry for α-SMA, fibronectin 
and collagen III was performed. Staining for collagen I was technically not feasible. 
Representative photomicrographs of α-SMA, fibronectin and collagen III staining 
are shown in Figure 4A. Microscopic analysis revealed no clear differences in 
α-SMA expression (similar to mRNA expression, Figure 3B). Quantitative analysis 
for fibronectin (Figure 4B) showed significantly (p < 0.01) increased expression 
levels in slices cultured in the presence of TGFβ1 (compared with medium) which 
was reduced by IFNγ (p < 0.05) and PPB-PEG-IFNγ (p = 0.05). Similar results were 
observed for the expression of collagen III (Figure 4C). PPB-HSA did not show any 
significant inhibitory effect on neither mRNA nor protein levels.
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Figure 4. Protein expression of α-SMA, fibronectin and collagen III in mPCKS cultured without 
TGFβ (medium), or with TGFβ in the presence of free IFNγ, PPB-PEG-IFNγ or PPB-HSA. (A) 
Photomicrographs of immunohistochemistry for α-SMA, fibronectin and collagen III on mPCKS after 
48 h of culture (magnification: 200×). Quantitative analysis of fibronectin (B) and collagen III (C) 
































Figure 5. Effect of IFNγ and PPB-PEG-IFNγ on the expression of fibrotic markers in mPCKS. (A) 
Schematic of targeted delivery of IFNγ to PDGFRβ-expressing myofibroblasts in mPCKS. Relative 
gene expression of (B) α-SMA, (C) collagen I, (D) fibronectin and (E) collagen III. *p < 0.05 versus 
medium; §p < 0.05 versus PPB-HSA.
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DISCUSSION
 The present study reveals the applicability of precision-cut kidney slices 
(PCKS) as: 1) an ex vivo model to study renal fibrogenesis, and 2) to test antifibrotic 
effects of IFNγ and targeted IFNγ aiming at reducing renal fibrosis. Specifically, the 
results demonstrate that incubation of mPCKS with TGFβ1 resulted in upregulation 
of fibronectin, collagen I and α-SMA expression which indicates that mPCKS 
represent an ideal model to study the onset of early fibrosis. Preserved expression 
of α-SMA suggests that fibroblasts remained active during culture, still intervention 
with free IFNγ and PPB-PEG-IFNγ clearly dampened TGFβ1-induced expression 
of fibronectin, collagen I and collagen III, thereby demonstrating the antifibrotic 
potential of both free and targeted IFNγ.
 Renal fibrosis results from excessive extracellular matrix accumulation and 
fibroblast proliferation (Duffield, 2014; LeBleu et al., 2013; Strutz and Zeisberg, 
2006). In order to develop an efficacious antifibrotic therapy, detailed knowledge of 
the underlying pathophysiology is necessary. It is already recognized for long time 
that in vitro studies can provide useful information on the mechanisms of disease 
(Westra et al., 2013; Westra et al., 2014a). PCTS, a three-dimensional multicellular 
environment, is a powerful model in order to provide insight into mechanisms of 
organ injury (Basile et al., 2012; Flamant et al., 2006; Nagae et al., 2008; Tharaux 
et al., 2000; van Swelm et al., 2014). Tissue slices have the biologically relevant 
structural features of in vivo tissues (de Kanter et al., 2002). PCTS have been widely 
used as ex vivo model to study development of liver and intestinal fibrosis (de Kanter 
et al., 2005). Ex vivo liver and intestinal slices maintain cell heterogeneity and tissue 
architecture, providing an appropriate tool to study multicellular processes such as 
fibrosis (de Kanter et al., 2005; van de Kerkhof et al., 2005; Westra et al., 2014b; de 
Graaf et al., 2010).
 In this study mouse kidney slices remained viable during the incubation 
period of 72 h, as determined by ATP content, a parameter generally used as 
indicator of viability. In addition, the increased expression of fibrosis markers in 
response to TGFβ1 also indicated that the relevant cells involved in fibrogenesis 
(i.e., fibroblasts) remained viable. It is generally accepted that stimulation with 
TGFβ1 induces differentiation of local fibroblasts into myofibroblasts which start to 
































that the same concentration of TGFβ1 (5 ng/ml) as used in current study induces 
collagen and α-SMA expression in NIH3T3 fibroblasts indicating TGFβ1-induced 
fibroblast to myofibroblast differentiation (Poosti et al., 2015). Although other 
renal cell types (including tubular epithelial cells, endothelial cells, podocytes, 
mesangial cells and pericytes) may also respond to TGFβ1 (Meng et al., 2015), 
our immunohistochemistry data support tubulointerstitial (myo)fibroblasts as main 
responders to TGFβ1 in mPCKS. Activation and/or proliferation of fibrogenic cells, 
which was accompanied by increased production of extracellular matrix, indicates 
that kidney slices could be a useful tool to study the effects of antifibrotic compounds 
in a multicellular environment. 
 IFNγ could be a useful therapeutic target to attenuate the development of 
renal fibrosis. Despite its potential effectiveness, application of IFNγ in clinical trials 
resulted in negative data (Cleland et al., 1996; Gu et al., 2005; King et al., 2009). 
The main reasons for the lack of clinical effects is the poor pharmacokinetic profile 
of IFNγ and the severe side effects due to ubiquitous expression of IFNγ receptors. 
Therefore, targeted delivery of IFNγ to key cells is thought to be a prerequisite to 
enhance its therapeutic efficacy and at the same time reduce systemic side effects. 
Recently, we studied antifibrotic effects of IFNγ and PEGylated IFNγ (PPB-PEG-
IFNγ) targeted to PDGFRβ-expressing myofibroblasts in an animal model of renal 
fibrosis (Poosti et al., 2014). Our strategy was to conjugate the cyclic PDGFRβ-
binding peptide (PPB) to mouse IFNγ via a PEG linker (PPB-PEG-IFNγ) to achieve 
specific delivery of IFNγ to PDGFRβ-expressing cells, due to upregulation of this 
receptor in fibrotic diseases. In order to check the applicability of the PCKS model 
for testing antifibrotic compounds, we examined IFNγ and targeted IFNγ (PPB-PEG-
IFNγ) on TGFβ-activated pre-fibrotic slices and on non-activated slices. Contrary to 
our expectation, PDGFRβ expression was not affected by TGFβ1. This might be 
explained by the fact that fibrosis is a multifactorial process, and therefore induction 
of PDGFRβ expression in vivo might be dependent on presence of different pro-
fibrotic cytokines rather than TGFβ1. Interestingly, in the group treated with IFNγ 
and PPB-PEG-IFNγ, we noticed a trend towards reduction of PDGFRβ expression 
which might explain their antifibrotic effects via down regulation of the PDGF/
PDGFRβ signaling pathway. We observed that both IFNγ and PPB-PEG-IFNγ 
exert antifibrotic effects as they significantly dampened TGFβ-induced fibronectin, 
collagen I and collagen III expression after 48 h incubation. These observations 
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confirmed our recent in vivo data (Poosti et al., 2015). However, in contrast to these 
in vivo data, in the current study PPB-PEG-IFNγ did not show higher efficacy when 
compared with free IFNγ. This can be explained by the fact that TGFβ1 did not 
increase PDGFRβ expression on mPCKS as described above. Besides, there is usually 
no added benefit of targeted compounds in vitro, since compounds can easily and 
effectively access the target cells, which is not the case after in vivo administration. 
Similar results were also obtained after exposure of NIH3T3 fibroblasts to IFNγ and 
PPB-PEG-IFNγ in the presence of TGFβ1 (Poosti et al., 2015). In fact, an effect 
after receptor-mediated endocytosis (as for PPB-PEG-IFNγ) sometimes may even be 
slower than a pharmacological effect of compounds directly to its receptor. The ex 
vivo studies with PPB-PEG-IFNγ therefore demonstrate that the targeted construct is 
pharmacologically active and was included as proof of concept.
 To determine whether the antifibrotic effects were not due to PPB-induced 
blockade of PDGFRβ-signaling, we coupled PPB to albumin (HSA). We did not 
observe remarkable antifibrotic effects of PPB-HSA ex vivo; only on the mRNA 
level a (non-significant) effect of PPB-HSA on collagen III expression was observed, 
indicating that most of the observed antifibrotic effects are IFNγ-mediated. Biological 
effects of IFNγ take place via the nuclear signaling sequence (NLS) which is present 
in the C-terminus region of IFNγ. IFNγ containing NLS is capable to bind to IFNγ 
receptor1 (IFNγR1) and initiate a cascade of events which is required for nuclear 
import of STAT1 and generation of biological activity. Activation of STAT1 by PEG-
PPB-IFNγ was previously shown (Bansal et al., 2011a). We propose that PEG-PPB-
IFNγ is taken up via PDGFRβ and the internalized construct next releases IFNγ or 
its metabolite which then binds to the intracellular part of IFNγR1 and activates the 
JAK/STAT pathway. However, this premise needs to be further explored.
 In summary, the mPCKS model is a novel tool to study the pathophysiology 
of early fibrotic processes not only in animal tissue, but also in (fibrotic) human 
kidney tissue. Importantly, from the results of this study we conclude that the in 
vivo observed antifibrotic effect of IFNγ and PPB-PEG-IFNγ can be successfully 
reproduced to great extent using mPCKS. This indicates that this ex vivo model is 
a useful tool for preclinical studies to test the efficacy of potential new antifibrotic 
drugs on fibroblast activation in a multicellular, pro-fibrotic milieu. In addition, 
the use of this model can contribute substantially to the reduction, refinement, and 
































are ongoing to investigate the application of non-fibrotic and fibrotic human PCKS 
in order to validate our targeting strategy in the human setting. We believe the PCKS 
model is able to bridge the gap between basic research performed using in vitro cell 
culture systems and translational human in vivo studies as schematically represented 
in Figure 6. The preclinical studies using PCKS should then pave the road towards 
clinical studies on cell-specific targeting of renal fibrosis.
Figure 6. The ex vivo PCKS model bridges the gap between basic research performed in in vitro cell 
culture models and translational in vivo human studies on pathophysiology and therapy of renal disease. 
In vitro cultured cells displayed are primary human tubular epithelial cells (PTECs).
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MATERIALS AND METHODS 
Mice
 Male C57BL/6 mice weighing 25-30 g were obtained from Harlan (Zeist, 
the Netherlands). Animals were housed in individual cages with free access to food 
and water. Before starting the experiment, animals were allowed to acclimatize 
for at least 7 days. The experimental protocol was approved by the Animal Ethical 
Committee of the University of Groningen (DEC 6427A).
Excision and preparation of mouse kidney slices 
 The protocol of the preparation and culture of kidney slices is illustrated in 
Figure 7 and a detailed description is given below.
Preparation of Krebs–Henseleit buffer (KHB)
 KHB was used as slicing buffer, and 10 l of a 10× concentrated KHB stock 
solution (10× KHB) were prepared by first dissolving 36.7 g CaCl2·2H2O in 5 l of 
ultrapure water (solution 1). Then, 37.3 g KCl, 690 g NaCl, 27.1 g MgSO4·7H2O 
and 16.3 g KH2PO4 were dissolved in ultrapure water to a volume of 5 l (solution 
2). Subsequently, solutions 1 and 2 were mixed and filtered through a 0.45-μm filter. 
This 10× KHB can be stored at 4°C for about 6 months. On the day of slicing, 5 l 1× 
KHB were prepared by dissolving 10.5 g NaHCO3 (Merck, Darmstadt, Germany), 
24.75 g D-glucose monohydrate (Merck, Darmstadt, Germany) and 11.9g HEPES 
(MP Biomedicals, Aurora, OH, USA) in ~2 l of ultrapure water at 4°C. Then, 500 ml 
10× KHB and ultrapure water at 4°C were added to yield a final volume of 5 l. This 
solution was kept at 0-4°C on melting ice, and was oxygenated with 95% O2/5% 
CO2 for 30 min on ice, using a gas dispersion tube with a fritted disc. The pH of the 
solution was adjusted to 7.42 by slowly adding 5 N NaOH solution. This solution 
can be stored for 24 h at 4°C. Before use, the buffer was reoxygenated and the pH 
































Williams medium E glutamax-I (WME) slice incubation medium 
 On the day of the experiment, slice incubation medium was prepared by 
adding 1.375 g D-glucose monohydrate (Merck, Darmstadt, Germany) and 500 μl 
gentamicin (50 mg/ml) (Invitrogen, Paisley, UK) to 500 ml Williams medium E with 
GlutaMAX (Invitrogen, Paisley, UK). If necessary, this solution can be stored for 24 
h at 4°C. 
Slicing procedure 
Preparations before start of slicing 
 KHB for slicing and WME (plus supplements) incubation medium were 
prepared as described above. WME incubation medium was transferred into culture 
plates, with 12-well plates requiring 1.3 ml of culture medium per well to support 
the tissue for 24 h. The volume-to-surface ratio of the culture medium is of great 
importance for optimal exchange of O2 and CO2 between the culture medium and 
the atmosphere of 80% O2/5% CO2, and the ratio of tissue to volume is important for 
sufficient supply of nutrients. The plates were pre-warmed and oxygenated by placing 
them in the shaking incubator at 37°C under 80% O2/5% CO2 for at least 30 min. 
The Krumdieck slicer (Alabama Research and Development, USA) was assembled 
according to the manufacturer’s instructions and pre-cooled by recirculating cooled 
water (4°C) through the cooling block, using a refrigerated circulator bath. 
Collection of kidney tissue 
 Mice were anesthetized under 2% isofluorane/O2 (Nicholas Piramal, London, 
UK), the right and left kidneys were retrieved as quickly as possible and placed into 
ice-cold University of Wisconsin (UW) organ preservation solution (DuPont Critical 
Care, Waukegab, IL, USA). All further steps up to incubation were performed on ice 
(at 0-4°C). The mouse kidneys were transferred to a Petri dish with a silicone insert 
in order to remove adipose tissue around the kidney. The whole kidney was then 
placed into the core cylinder. 
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Preparation of kidney slices 
 The slicer was filled with ice-cold oxygenated KHB through the glass-
trap assembly. It was ensured that the buffer reached the level required for proper 
functioning of the pump and that the tissue core was completely submerged. For 
mouse kidney slices, whole kidneys were transferred from the ice-cold UW solution 
used for storage into the cylindrical core holder of the slicer. 
 Slices were cut using the Krumdieck slicer at a speed setting of 30-40. The 
wet weight of the first few slices was checked as an indication of slice thickness 
after carefully blotting the slices on a smooth, not too absorptive paper to remove 
adherent water, with an optimal wet weight of 5 mg. 
 If necessary, the cutting thickness was adjusted by turning the graduated 
thickness control knob until the required wet weight was reached. The slice thickness 
can be slightly increased by placing weights on top of the tissue core holder, which 
may also facilitate the slicing of hard (fibrotic) kidney tissue. Kidney slices that 
are too thick (>400 μm) may develop necrosis in the center of the slice, as the 
diffusion distance for nutrients and oxygen is too long. After slicing one core, the 
slices were removed from the glass trap by opening the tap, collecting them in a 
beaker and placing them immediately on ice. Slices were selected on the basis of 
their appearance, with good slices having an equal thickness, uniform color and 
smooth edges. Selected slices were transferred into fresh ice-cold UW and stored on 
ice. 
A spatula (not forceps) was used to avoid damaging the slices. The KHB 
slicing buffer was replaced by fresh, ice-cold and oxygenated KHB every 15-30 min, 
and the knife was replaced when slice quality (judged by eye) decreased. 
Experimental setup slice cultures 
 In this study three independent experiments were performed, each using 
four kidneys (2 mice) from which in total four cores were drilled. After slicing, slices 
were pooled before plating them for culture. ATP measurements were performed 
on single slices. For mRNA expression analysis, in each experiment slices were 
cultured in triplicate for each condition after which they were pooled for RNA 
isolation. Histological analyses were performed on single slices per condition in 
































Incubation of kidney slices
 Kidney slices were washed quickly by gently transferring them into WME 
to remove the UW. Before adding medium and mPCKS, 12 well plates were coated 
with 10% bovine serum albumin (BSA) in milliQ water for 30 minutes. The solution 
was removed and plates were air dried. Slices were then incubated in the coated plates 
containing per well 1.3 ml Williams Medium E glutamax-I (Gibco, Paisley, UK) per 
well supplemented with 25 mM D-glucose and 50 µg/ml gentamycin. Medium was 
pre-warmed and gassed with 80% O2/5% CO2 before it was added to the wells. Slices 
were individually transferred to the wells of a culture plate placed on a surgical 
mattress to maintain the medium at 37oC. Plates were immediately transferred back 
in a shaking CO2 incubator (90 cycles/min) under continuous supply of 80% O2/5% 
CO2, as the pH of the medium rapidly changes in normal atmosphere. Slices were 
incubated for 1, 6, 12, 24, 48 or 72 h. When appropriate, after 24 and 48 h slices were 
transferred to new plates with fresh medium. For refreshing, new culture plates were 
filled with medium, and the plates were pre-warmed and oxygenated. The incubated 
plates and new plates were placed on a surgical mattress to maintain the temperature 
at 37°C. The slices were quickly transferred from the incubated plates into the new 
plates with a spatula and placed in the incubator. 
Uptake of FITC-lysozyme by mPCKS 
 FITC-lysozyme was prepared as described before (Kok et al., 1998). Briefly, 
500 µl of 1 mg/ml FITC (Thermo Scientific, Wilmington, USA) was carefully mixed 
with 5 ml of 2 mg/ml lysozyme solution (Sigma-Aldrich, Saint Louis, USA) for 8 
h at 4 °C in the dark, dialysed against water and finally lyophilized. Mouse kidney 
slices were incubated up to 3 h with 1 mg/ml FITC-lysozyme. After 1 and 3 h, the 
mPCKS were embedded in Tissue-tek (Sakura, Japan) and snap-frozen in isopentane 
(-80 °C). They were stored at -80 °C until 4 μm cryosections were cut perpendicular 
to the surface of the slices. Cross-sections were allowed to dry on a glass microscope 
slide and covered with Citifluor (Citifluor Ltd., London, UK). Slides were examined 
using a high-end fully motorized Zeiss AxioObserver Z1 microscope and images 
were acquired using TissueFAXS Image Analysis Software (TissueGnostics, 
Austria). Images were converted to red/green pseudo-colours using lookup tables in 
ImageJ 1.47v (http://imagej.nih.gov/ij).
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Induction of renal pre-fibrosis ex vivo
 In order to induce renal pre-fibrosis ex vivo, slices were incubated for 
48 h in the presence of recombinant human TGFβ1 (5 ng/ml, hTGFβ1, Roche, 
Mannheim, Germany). Medium without TGFβ1 was used for comparison. After 24 
h of incubation, slices were transferred to new coated plates with fresh medium 
containing TGFβ1.
Figure 7. Schematic representation of the experimental approach for obtaining and culturing mPCKS. 
(1) Mouse kidneys (n = 3) were excised under isofluorane/O2 anesthesia and placed into ice-cold UW 
preservation solution. (2) Cores were drilled and immediately transferred to the cylindrical core holder 
of a Krumdieck slicer and cut into 5-mm diameter slices. (3) High-quality slices (equal thickness at 
all sides and smooth edges) were transferred to 12-well plates using a spatula to avoid damaging of 
the slices, and (4) were placed in a shaking (90 cycles/min) incubator under continuous supply of 80% 
O2/5% CO2 at 37°C.
Synthesis of conjugates
 PPB-PEG-IFNγ (in which PPB is the PDGFR recognizing binding peptide) 
































PEG-IFNγ, recombinant murine IFNγ (0.256 nmol, Peprotech, London, UK) was 
mixed with 12.8 nmol of maleimide-PEG-succinimidyl carboxy methyl ester 
(Mal-PEG-SCM, 2 KDa, Creative PEGworks, Winston-Salem, NC) for 2 h and 
dialyzed overnight against PBS using 10 KDa dispodialyzer (Harvard Apparatus, 
Holliston, Massachusetts, USA). The dialyzed sample was then mixed with SATA 
(succinimidyl acetyltioacetate)-modified PPB (PPB-ATA, 25.6 nmol) in the presence 
of a deacetylating reagent. Finally, PPB-PEG-IFNγ was extensively dialyzed against 
PBS and stored at -80°C.
 For PPB-HSA, human serum albumin (HSA, 1.5 µmol dissolved in PBS) was 
mixed with γ-maleimidobutyryloxy-succinimide ester (GMBS, 30 µmol, dissolved 
in DMF) for 2 h and extensively dialyzed against PBS using 10 KDa cut-off dialysis 
membrane cassette (Thermo Scientific, Rockford, IL, USA). Next, PPB-ATA (34.5 
µmol; dissolved in DMF) was added to the GMBS-modified HSA for overnight, and 
dialyzed against PBS. The final product (PPB-HSA) was freeze-dried for storage at 
-20°C. 
Antifibrotic effects of free IFNγ and PPB-PEG-IFNγ 
 To determine the antifibrotic effects of free IFNγ and PPB-PEG-IFNγ, slices 
were incubated for 48 h with free IFNγ, PPB-PEG-IFNγ, PPB-HSA (equivalent 1 µg/
ml) or medium alone in the presence or absence of TGFβ1 as described above. After 
the first 24 h of incubation slices were transferred to new 12 well plates with fresh 
medium containing TGFβ1 and the respective antifibrotic compounds. TGFβ1 and 
IFNγ constructs were administered simultaneously. The concentration of 1 µg/ml 
of IFNγ constructs was chosen based on results from previous in vitro experiments 
(Bansal et al., 2011a; Poosti et al., 2014).
Viability of mPKCS: ATP and protein content 
 The general viability of the PCKS during culture was determined by measuring 
ATP content of the slices. For ATP measurements, single slices were transferred to a 
sonication solution containing 70% ethanol (v/v) and 2 mM EDTA (pH 10.9), snap-
frozen in liquid nitrogen and stored at -80°C until analysis. After homogenization 
using a Mini-BeadBeater-8 (BioSpec, Bartlesville, OK, USA), the samples were 
centrifuged for 2 min. at 13000 rpm. The supernatant was diluted 10 times with 
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0.1 M Tris–HCl/2 mM EDTA buffer (pH 7.8) to lower the ethanol concentration 
and used to measure ATP contents using the ATP Bioluminescence assay kit CLSII 
(Roche diagnostics, Mannheim, Germany) according to the manufacturer’s protocol. 
The remaining pellet was used to determine the protein content of the mPCKS by 
dissolving it in 200 μL of 5 M NaOH for 30 minutes. After dilution with water to 
a concentration of 1 M NaOH, the protein content of the samples was determined 
using the Lowry method (Bio-Rad DC Protein Assay, Bio-Rad, Munich, Germany). 
BSA was used for the calibration curve. ATP values (in pmol) were divided by the 
total protein content (in μg) of the respective slices and expressed as the ratio ATP/
protein. 
Quantitative Real-Time PCR
 In order to determine TGFβ-induced pre-fibrosis, and to examine the effect of 
IFNγ and PPB-PEG-IFNγ, gene expression of fibrosis markers [alpha smooth muscle 
actin (α-SMA), fibronectin (Fn), collagens I & III] was measured using quantitative 
Real-Time (qRT) PCR. The triplicate slices were pooled and snap-frozen. Total 
RNA from kidney slices was extracted using the RNeasy Mini Kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. The RNA concentrations 
were measured on a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, 
Wilmington, USA). Single-stranded cDNA was synthesized using Superscript II and 
random hexamer primers (Invitrogen, Carlsbad, CA, USA) in a volume of 20 µl. 
cDNA was first diluted to a concentration of 2 ng/μl and 2.5 μl/reaction (5 ng) and was 
then used for qRT-PCR analysis. PCR reactions were performed in a 10 µl reaction 
volume containing 1 x qPCR master mix (Eurogentec, Liege, Belgium) and 1x 
TaqMan Gene Expression Assay mix (Applied Biosystems, Forster City, CA, USA). 
The TaqMan assay numbers were as follows: Ywhaz: Mm03950126_s1, Col1a1: 
Mm00801666_g1, Col3a1: Mm01254476_m1, α-SMA/Acta2: Mm01546133_m1, 
Fn: Mm01256744_m1, MHCII/CD74: Mm00658576_m1. qRT-PCR reactions 
were performed on a ABI7900HT thermal cycler (Biosystems, Forster City, CA, 
USA). Relative gene expression was calculated using the 2-ΔCt method with Ywhaz 


































 Study of histological changes was performed on 2 µm sections from 
formalin-fixed paraffin-embedded slices. For immunohistochemistry the following 
primary antibodies were used: anti-alpha smooth muscle actin (α-SMA, clone ASM-
1, Progen Biotechnik, Heidelberg, Germany); anti-fibronectin (ab6584, Abcam, 
Cambridge, UK); and anti-collagen III (s1330-01, SouthernBiotech, Birmingham, 
Alabama, USA). Sections were deparaffinised in xylene and rehydrated in graded 
alcohol and distilled water. Antigen retrieval was achieved by overnight incubation 
at 60ºC in 0.1 M Tris/HCl buffer (pH 9.0) for fibronectin and collagen III staining. 
No antigen retrieval was performed for α-SMA staining. Endogenous peroxidase 
activity was blocked with 0.03% H2O2 (in PBS) for 30 min. Primary antibody binding 
was detected by sequential incubations with horseradish peroxidase (HRP)-labeled 
appropriate secondary and tertiary antibodies (obtained from DAKO, Glostrup, 
Denmark). Peroxidase activity was visualized using 3,3’-diaminobenzidine 
tetrahydrochloride (DAKO, Glostrup, Denmark) as chromogen (10 min incubation). 
Sections were counterstained with haematoxylin for 1 minute and mounted with 
Kaiser’s glycerin gelatin.
Quantification of immunostaining 
 To quantify immunostaining of fibronectin and collagen III, sections were 
first scanned using a NanoZoomer HT (Hamamatsu Photonics K.K., Shizuoka 
Pref., Japan). Next, the extent of fibronectin and collagen III positive staining was 
measured (number of positive pixels) using Aperio ImageScope software (version 
9.1.772.1570, Aperio Technologies Inc, Vista, CA, USA).  
Statistical analyses 
 Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad 
Software Inc, La Jolla, CA, USA). Data are expressed as mean ± standard error of 
the mean of three independent experiments. Differences between multiple groups 
were calculated using ANOVA. Comparisons of two groups were performed using 
Student’s t-test. p < 0.05 was considered statistically significant.
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